In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Xylem Inc. trades 41% below its high-confidence fair value estimate of $139.92, indicating potential undervaluation. Its strong liquidity and leverage scores contrast with moderate profitability and growth, signaling balanced financial health. Monte Carlo analysis reveals substantial upside volatility but notable downside risk (38.9%), reflecting mixed risk-reward characteristics.